

CURRENT TRENDS, MODERN SYNTHETIC APPROACH, SAR AND BIOLOGICAL ACTIVITIES OF BENZIMIDAZOLE DERIVATIVES

Nihar Ranjan Kar ¹, Prasanthi Samathoti ², S. Muralitharan ³,
Sruti Ranjan Mishra ⁴, Aditya Vikram Jain ⁵, Preeti Yadav ⁶ and
G. Dharmamoorthy ^{7*}

¹ Assistant Professor, Centurion University of Technology and Management,
Gopalpur, Balasore, Odisha, India.

² Associate Professor, MB School of Pharmaceutical Sciences,
Mohan Babu University, Sree Sainath Nagar, Tirupati, Andhra Pradesh.

³ Tamilnadu Physical Education and Sports University, Chennai.

⁴ Professor Cum Principal, Danteswari College of Pharmacy,
Borpadar, Raipur Road, Jagdalpur, Chhattisgarh, C.G.

^{5,6} Associate Professor, Department of Pharmacy, IIMT College of Medical Sciences,
IIMT University, Ganga Nagar, Meerut.

⁷ Professor, Department of Pharmaceutical Analysis, MB School of Pharmaceutical Sciences,
Mohan Babu University, (Erstwhile Sree Vidyaniketan College of Pharmacy), Tirupati.

*Corresponding Author Email: dharmamoorthy111@gmail.com

DOI: 10.5281/zenodo.8339770

Abstract

Background: Benzimidazole is a heterocyclic compound with a benzene ring fused to an imidazole ring. It is commercially available as a white, odorless, and tasteless powder. O-phenylenediamine and formic acid are condensed to form benzimidazole. The most common benzimidazole substance found in nature is N- riosyldimethylbenzimidazole, which functions as an axial ligand for cobalt in vitamin B12. **Aim:** The main objective of the review is to explore Current trends, modern synthetic approach, SAR and Biological activities of benzimidazole derivatives. **Method and material:** All the data were collected from online published article which in indexed in SCOPUS, WOS, and UGC. **Result:** Benzimidazole derivatives are generally well-tolerated, but they can cause side effects such as nausea, vomiting, and diarrhea. They can also interact with other medications, so it is important to talk to your doctor before taking them. **Conclusion:** In order to inform the reader on the chemical and pharmacological properties of these compounds, the goal of this article is to provide them a thorough overview of the substituted benzimidazoles.

Keywords: Benzimidazole, heterocyclic compound, imidazole ring, N- riosyldimethylbenzimidazole

INTRODUCTION

In the disciplines of medical and pharmaceutical chemistry, benzoimidazole is well recognised as a substantial and prominent component of physiologically relevant molecules [1,2,3,4,5]. These heterocycles continue to be essential structural motifs in the thoughtful creation of novel medications due to their wide range of biological effects.

The substance has a variety of pharmacological activities, including antioxidant, antiviral, antibacterial, anticancer, and anti-inflammatory actions [5,6,7,8]. A common class of chemotherapeutic medications continues to be molecules that interact with DNA/RNA in medicinal chemistry [9,10,11,12].

Amidines are essential structural elements of many physiologically active chemicals, such as significant pharmaceutical and biochemical agents. Through interactions with hydrogen bonds and electrostatic fields, these derivatives dramatically increase the stability of the molecule/biological target combination [13,14]. It has been shown in a

number of earlier investigations that adding one or two positively charged amidine moieties to the terminal of heteroaromatic benzimidazole/benzothiazole derivatives significantly improves their biological activity [13,14,15,16,17,18,19].

Furthermore, the heteroaromatic derivative's functionalization was made easier by the presence and arrangement of amidine groups, which pointed it in the direction of interactions with negatively charged molecules like DNA and RNA. For instance, it has been shown that specific benzimidazole and benzothiazole derivatives with an amidine group have strong antitumor effects by binding to single-stranded RNA, the minor groove of adenine-thymine DNA, or the adenine-thymine rich region of cytosine-thymine DNA [20,21].

They can also intercalate into double-stranded RNA and cytosine-thymine DNA. Additionally, research on the antibacterial properties of dicationic compounds with amidine moiety, such as pentamidine, has been going on since the turn of the 20th century.

These studies have shown its effectiveness in treating a number of disorders [22,23]. It has been shown that several derivatives with comparable properties display binding affinity to the minor groove of DNA at AT-rich sites [24,25]. Many biophysical studies [26] as well as many crystallographic analysis have supported this claim. The chemical characteristics of 2,5-disubstituted furane derivatives, which might include one or two amidine functional groups, have received a lot of attention in study.

Benzimidazole is a heterocyclic compound with a benzene ring fused to an imidazole ring. It is commercially available as a white, odorless, and tasteless powder. O-phenylenediamine and formic acid are condensed to form benzimidazole. The most common benzimidazole substance found in nature is N-riboflavin dimethylbenzimidazole, which functions as an axial ligand for cobalt in vitamin B12. Benzimidazole and its derivatives have a wide range of pharmacological activities, including antihelminthic, antifungal, antidiabetic, anticancer, and antiviral. They are used in the treatment of a variety of diseases, including parasitic infections, fungal infections, diabetes, cancer, and HIV.

The mechanism of action of benzimidazole derivatives varies depending on the specific compound. However, they generally work by interfering with the metabolism of the target organism. For example, antihelminthic benzimidazole derivatives disrupt the metabolism of parasitic worms, leading to their death. Antifungal benzimidazole derivatives inhibit the growth of fungi by interfering with their cell wall synthesis. Antidiabetic benzimidazole derivatives improve insulin sensitivity and help to lower blood sugar levels.

Benzimidazole derivatives are generally well-tolerated, but they can cause side effects such as nausea, vomiting, and diarrhea. They can also interact with other medications, so it is important to talk to your doctor before taking them. The article you mentioned is a comprehensive review of the chemistry and pharmacological properties of substituted benzimidazoles. It is a valuable resource for anyone interested in learning more about this important class of compounds.

Here are some additional information about the pharmacological properties of benzimidazole derivatives: [27-30]

- **Antihelminthic:** Benzimidazole derivatives are used to treat a variety of parasitic infections, including roundworms, tapeworms, and hookworms. They work by disrupting the metabolism of the parasites, leading to their death.
- **Antifungal:** Benzimidazole derivatives are used to treat a variety of fungal infections, including athlete's foot, jock itch, and ringworm. They work by inhibiting the growth of fungi by interfering with their cell wall synthesis.
- **Antidiabetic:** Benzimidazole derivatives are used to treat type 2 diabetes. They work by improving insulin sensitivity and helping to lower blood sugar levels.
- **Anticancer:** Benzimidazole derivatives are being investigated for the treatment of cancer. They work by interfering with the growth and spread of cancer cells.
- **Antiviral:** Benzimidazole derivatives are being investigated for the treatment of HIV and other viruses. They work by interfering with the replication of the viruses.

Benzimidazole derivatives are a promising class of compounds with a wide range of therapeutic applications. They continue to be an important area of research for the development of new drugs to treat a variety of diseases.




Fig 1: 3D Model of 1H-benzimidazole

In 1944, Woolley proposed that benzimidazole may exhibit comparable characteristics to purines, thereby leading to the first recognition of the therapeutic potential associated with the benzimidazole nucleus. Brink's investigation led to the identification of 5,6-dimethylbenzimidazole as a breakdown product of vitamin B12, afterwards revealing that various compounds of Brink had properties similar to vitamin B12. The first discoveries prompted extensive research on the nucleus, with the aim of investigating its numerous functions and applications. The benzimidazole molecule exhibits a diverse array of pharmacokinetic and pharmacological attributes in its derivative forms.

The benzimidazole nucleus is a bioactive heterocyclic compound that exhibits a diverse range of biological properties. These properties encompass antiparasitic, anticonvulsant, analgesic, antihistaminic, antiulcer, antihypertensive, antiviral, anticancer, antifungal, anti-inflammatory, proton pump inhibitory, and anticoagulant activities. A variety of drugs, such as albendazole, mebendazole, and thiabendazole, have been developed by the process of optimising the substituents around the benzimidazole nucleus. The term "benzimidazole" is often used at positions 3, 5, and 8.

A number of benzimidazole compounds, namely LY 12277172 and LY 127123, have shown notable effectiveness in inhibiting picorna viruses. The user's text is too short to be rewritten in an academic manner. Previous studies have shown the use of certain derivatives of benzimidazoles as pharmacophores in the development of anticonvulsant drugs, provided that appropriate substituents are present. In the last decade, there has been a notable surge in research efforts focused on the synthesis of bioactive molecules derived from benzimidazole. The benzimidazole nucleus is now used in the synthesis of essential intermediates for many chemical processes. [31-35]

Chemistry of Benzimidazoles

The chemistry of benzimidazoles is a vast and complex field. Here is a brief overview of some of the key concepts:

- **Structure:** Benzimidazole is a heterocyclic compound with a benzene ring fused to an imidazole ring. The imidazole ring is a five-membered ring with two nitrogen atoms. The benzene ring is a six-membered ring with alternating single and double bonds.
- **Synthesis:** There are many different ways to synthesize benzimidazoles. One common method is to condense o-phenylenediamine with a carboxylic acid. Another method is to condense a substituted hydrazine with a carbonyl compound.
- **Reactivity:** Benzimidazoles are relatively reactive compounds. They can undergo a variety of reactions, including electrophilic substitution, nucleophilic substitution, and addition reactions.
- **Pharmacological properties:** Benzimidazoles have a wide range of pharmacological properties. They are used in the treatment of a variety of diseases, including parasitic infections, fungal infections, diabetes, cancer, and HIV.

The chemistry of benzimidazoles is a constantly evolving field. New methods of synthesis are being developed, and new pharmacological applications are being discovered. Benzimidazoles are a promising class of compounds with the potential to treat a variety of diseases.

Here are some specific examples of the chemistry of benzimidazoles:

- **Electrophilic substitution:** Benzimidazoles can undergo electrophilic substitution reactions at the nitrogen atoms in the imidazole ring. This can be used to introduce substituents into the ring.
- **Nucleophilic substitution:** Benzimidazoles can also undergo nucleophilic substitution reactions at the nitrogen atoms in the imidazole ring. This can be used to synthesize new compounds with different biological activities.
- **Addition reactions:** Benzimidazoles can undergo addition reactions with alkenes and alkynes. This can be used to synthesize new compounds with different properties.

The chemistry of benzimidazoles is a complex and fascinating field. It is a valuable tool for the synthesis of new compounds with potential therapeutic applications.

The benzimidazoles consist of a phenyl ring that is fused to an imidazole ring, as seen in the structural representation of benzimidazole illustrated in Figure 2. [36-37]




Fig 2: Phenyl ring that is fused to an imidazole ring

The first benzimidazole chemical was successfully synthesised by Hoebrecker in 1872. Included in this accomplishment was the reduction of 2-nitro-4-methylacetanilide, which produced 2,5 (or 2,6)-dimethylbenzimidazole. The substances known as benzimidazoles may also be referred to as benzoglyoxalines or benzimidazoles. Particularly in previous literature, these substances have also been referred to as o-phenylenediamine derivatives. This nomenclature would identify benzimidazole as methenyl-o-phenylenediamine and 2-methylbenzimidazole as ethenyl-o-phenylenediamine. These substances have also been classified as derivatives of the mixture that makes up the ring's imidazole moiety. It should be noted that benzimidazole has also been known by other names, including o-phenyleneformamidine, 2 (3H)-benzimidazolone, and 2 (3H) benzimidazolethione, which are also known as o-phenyleneurea and o-phenylenethiourea, respectively. These names are shown in Figures 3 and 4, respectively.




Fig 3: 2 (3H)- benzimidazolone




Fig 4: 2 (3H) benzimidazolethione

Multiple Methods For Producing Benzimidazoles:

There are many different methods for producing benzimidazoles. Some of the most common methods include:

1. Condensation of o-phenylenediamine with a carboxylic acid: This is the most common method for producing benzimidazoles. O-phenylenediamine is condensed with a carboxylic acid in the presence of a base, such as sodium hydroxide. The reaction product is a benzimidazole derivative. [38]




Fig. 5: O-phenylenediamine is condensed with a carboxylic acid

2. Condensation of a substituted hydrazine with a carbonyl compound: This method is similar to the previous method, but a substituted hydrazine is used instead of o-phenylenediamine. The substituted hydrazine is condensed with a carbonyl compound in the presence of a base. The reaction product is a benzimidazole derivative. [39-40]




Fig. 6: Preparation of 4-[(1H-benzimidazol-2-yl)sulfanyl]benzaldehyde and 2-((4-[(1H-benzimidazol-2-yl)sulfanyl]phenyl)methylidene)hydrazine-1-carbothioamide.

3. Reaction of a benzimidazole with a diazonium salt: A benzimidazole can be reacted with a diazonium salt to produce a new benzimidazole derivative. The diazonium salt is generated in situ from a primary aromatic amine. The reaction is carried out in the presence of a base. [39-40]




Fig 7: Reaction with a diazonium salt

4. Ring expansion of a succinimide: A succinimide can be ring-expanded to produce a benzimidazole. The ring expansion is catalyzed by a base.

5. Palladium-catalyzed coupling reaction: A benzimidazole can be synthesized by a palladium-catalyzed coupling reaction between an aryl halide and a hydrazine. The reaction is carried out in the presence of a base.

These are just a few of the many methods that can be used to produce benzimidazoles. The choice of method will depend on the specific benzimidazole derivative that is desired. [41-47]

General Procedure for the Synthesis of 2-Substituted Benzimidazoles

Sure, here is a general procedure for the synthesis of 2-substituted benzimidazoles:

1. Prepare the carbonyl compound. The carbonyl compound can be an aldehyde, ketone, carboxylic acid, or acid anhydride. The carbonyl compound should be dry and free of impurities.
2. Prepare the o-phenylenediamine. O-phenylenediamine is a solid, so it should be dissolved in a solvent, such as ethanol or methanol.
3. Combine the carbonyl compound and o-phenylenediamine in a reaction vessel. The reaction vessel should be dry and inert.
4. Add a base to the reaction vessel. The base will help to promote the condensation reaction. A common base is sodium hydroxide.
5. Heat the reaction mixture. The reaction mixture should be heated to a temperature of 100-150 degrees Celsius.
6. Monitor the reaction. The reaction should be monitored to ensure that it is complete.
7. Isolate the product. The product can be isolated by distillation or extraction.

Here is a specific example of the synthesis of a 2-substituted benzimidazole: [48-57]

- **Starting materials:**
 - o-Phenylenediamine
 - Acetaldehyde
 - Sodium hydroxide
- **Procedure:**
 - Dissolve o-phenylenediamine in ethanol.
 - Add acetaldehyde to the solution.
 - Add sodium hydroxide to the solution.
 - Heat the solution to 100 degrees Celsius.
 - Monitor the reaction until it is complete.
 - Distil the product to isolate it.

The product of this reaction is 2-acetylbenzimidazole.




Fig 8: Synthesis of 2-Substituted Benzimidazoles

Biological Importance of Benzimidazole

The "Master Key," also known as the benzimidazole nucleus, is the key core of multiple compounds that act at various sites to create a variety of pharmacological effects. A broad variety of chemical compounds may fit into the seven places of the benzimidazole nucleus, however the majority of physiologically active benzimidazole-based compounds include functional groups at positions 1, 2, and/or 5(or 6). As a result, the compounds contain derivatives of the nucleus that are mono-, di-, or tri-substituted. Antihypertensive, anti-inflammatory, antibacterial, antifungal, anthelmintic, antiviral, antioxidant, antiulcer, anticancer, and psychoactivity are a few of the main effects. As mentioned in, there are several products that include benzimidazole. [58-69]

Benzimidazole and its derivatives have a wide range of biological activities, including antihelminthic, antifungal, antidiabetic, anticancer, and antiviral. They are used in the treatment of a variety of diseases, including parasitic infections, fungal infections, diabetes, cancer, and HIV.

The biological importance of benzimidazole can be summarized as follows:

- **Antihelminthic:** Benzimidazole derivatives are used to treat a variety of parasitic infections, including roundworms, tapeworms, and hookworms. They work by disrupting the metabolism of the parasites, leading to their death.
- **Antifungal:** Benzimidazole derivatives are used to treat a variety of fungal infections, including athlete's foot, jock itch, and ringworm. They work by inhibiting the growth of fungi by interfering with their cell wall synthesis.
- **Antidiabetic:** Benzimidazole derivatives are used to treat type 2 diabetes. They work by improving insulin sensitivity and helping to lower blood sugar levels.
- **Anticancer:** Benzimidazole derivatives are being investigated for the treatment of cancer. They work by interfering with the growth and spread of cancer cells.
- **Antiviral:** Benzimidazole derivatives are being investigated for the treatment of HIV and other viruses. They work by interfering with the replication of the viruses.

Benzimidazole derivatives are a promising class of compounds with a wide range of therapeutic applications. They continue to be an important area of research for the development of new drugs to treat a variety of diseases.

Here are some specific examples of the biological importance of benzimidazole:

- **Albendazole:** Albendazole is an antihelminthic drug that is used to treat a variety of parasitic infections, including roundworms, tapeworms, and hookworms. It is also used to treat giardiasis, an infection caused by a parasite called *Giardia lamblia*.
- **Mebendazole:** Mebendazole is another antihelminthic drug that is also used to treat giardiasis. It is also used to treat pinworms and whipworms.
- **Thiabendazole:** Thiabendazole is an antifungal drug that is used to treat a variety of fungal infections, including athlete's foot, jock itch, and ringworm. It is also used to treat strongyloidiasis, an infection caused by a parasitic worm called *Strongyloides stercoralis*.
- **Voriconazole:** Voriconazole is an antifungal drug that is used to treat more serious fungal infections, such as those that affect the lungs or the blood. It is also used to prevent fungal infections in people who are at high risk, such as those who have had an organ transplant.
- **Olaparib:** Olaparib is a PARP inhibitor that is used to treat certain types of cancer, such as ovarian cancer and breast cancer. PARP inhibitors work by blocking a protein that is involved in DNA repair. This can lead to the death of cancer cells.

These are just a few examples of the many ways that benzimidazole and its derivatives are used in medicine. Benzimidazole is a versatile compound with a wide range of potential therapeutic applications. It is an important area of research for the development of new drugs to treat a variety of diseases. [69-70]




Fig 9: Benzimidazole, a multifunctional nucleus

Structural Activity Relationship of benzimidazole:

The structural activity relationship (SAR) of benzimidazoles refers to the relationship between the structure of a benzimidazole compound and its biological activity. SAR studies have shown that the structure of the benzimidazole ring is essential for its biological activity. The substituents on the benzimidazole ring can also significantly alter its biological activity.

Here are some of the key findings of SAR studies on benzimidazoles:

- The presence of the imidazole ring is essential for biological activity.
- The substituents on the 2-position of the benzimidazole ring have the greatest impact on biological activity.
- Electron-withdrawing substituents on the 2-position of the benzimidazole ring tend to increase biological activity.
- Electron-donating substituents on the 2-position of the benzimidazole ring tend to decrease biological activity.
- The substituents on the 5-position of the benzimidazole ring also have an impact on biological activity, but to a lesser extent than the substituents on the 2-position.

SAR studies have been used to design new benzimidazole compounds with improved biological activity. For example, SAR studies have been used to design new antifungal benzimidazole compounds that are more effective against drug-resistant fungi.

Here are some examples of how the SAR of benzimidazoles has been used to design new drugs:

- The antihelminthic drug albendazole was designed based on SAR studies. Albendazole has a 2-chlorophenyl substituent, which is an electron-withdrawing group that increases its biological activity.
- The antifungal drug voriconazole was also designed based on SAR studies. Voriconazole has a 5-fluorophenyl substituent, which is an electron-withdrawing group that increases its biological activity.
- The PARP inhibitor olaparib was designed based on SAR studies. Olaparib has a 4-methylpyrimidine substituent, which is an electron-donating group that decreases its toxicity.

SAR studies are a valuable tool for the design of new benzimidazole compounds with improved biological activity. They are an important part of the drug discovery process. [71-72]




Fig 10: Structural Activity Relationship of benzimidazole

CONCLUSION

Anti-microbial, anti-viral, anti-diabetic, and anti-cancer activity are some of the biological benefits that may be attributed to benzimidazoles, which belong to a possible family of bioactive heterocyclic compounds and demonstrate these characteristics. This exhaustive review describes the chemistry of a number of different derivatives of substituted benzimidazole as well as the antibacterial activity of these compounds.

References

1. Silverman, R.B. *The Organic Chemistry of Drug Design and Drug Action*; Elsevier Academic Press: Amsterdam, The Netherlands, 2004. [[Google Scholar](#)]
2. Sharma, P.C.; Sinhar, A.; Sharma, A.; Rajak, H.; Pal Pathak, D. Medicinal significance of benzothiazole scaffold: An insight view. *J. Enzyme Inhib. Med. Chem.* **2013**, *28*, 240–266. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
3. Bansal, Y.; Silakari, O. The therapeutic journey of benzimidazoles: A review. *Bioorg. Med. Chem.* **2012**, *20*, 6208–6236. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
4. Yadav, G.; Ganguly, S. Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review. *Eur. J. Med. Chem.* **2015**, *97*, 419–443. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
5. Irfan, A.; Batool, F.; Naqvi, S.A.Z.; Islam, A.; Osman, S.M.; Nocentini, A.; Alissa, S.A.; Supuran, C.T. Benzothiazole derivatives as anticancer agents. *J. Enzyme Inhib. Med. Chem.* **2019**, *35*, 265–279. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)][[Green Version](#)]
6. Shah, K.; Chhabra, S.; Shrivastava, S.K.; Mishra, P. Benzimidazole: A promising pharmacophore. *Med. Chem. Res.* **2013**, *22*, 5077–5104. [[Google Scholar](#)] [[CrossRef](#)]
7. Rescifina, A.; Zagni, C.; Varrica, M.G.; Pistarà, V.; Corsaro, A. Recent advances in small organic molecules as DNA intercalating agents: Synthesis, activity, and modeling. *Eur. J. Med. Chem.* **2014**, *74*, 95–115. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
8. Rupinder Gill, K.; Rawal, R.K.; Bariwal, J. Recent Advances in the Chemistry and Biology of Benzothiazoles. *Arch. Pharm. Chem. Life Sci.* **2015**, *348*, 155–178. [[Google Scholar](#)] [[CrossRef](#)]
9. Buric, A.J.; Dickerhoff, J.; Yang, D. Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug—Design and Mechanism of Action. *Molecules* **2021**, *26*, 4132. [[Google Scholar](#)] [[CrossRef](#)]
10. Khadieva, A.; Mostovaya, O.; Padnya, P.; Kalinin, V.; Grishaev, D.; Tumakov, D.; Stoikov, I. Arylamine Analogs of Methylene Blue: Substituent Effect on Aggregation Behavior and DNA Binding. *Int. J. Mol. Sci.* **2021**, *22*, 5847. [[Google Scholar](#)] [[CrossRef](#)]
11. Wróbel, A.; Baradyn, M.; Ratkiewicz, A.; Droydowska, D. Synthesis, Biological Activity, and Molecular Dynamics Study of Novel Series of a Trimethoprim Analogs as Multi-Targeted Compounds: Dihydrofolate Reductase (DHFR) Inhibitors and DNA-Binding Agents. *Int. J. Mol. Sci.* **2021**, *22*, 3685. [[Google Scholar](#)] [[CrossRef](#)]
12. Depauw, S.; Lambert, M.; Jambon, S.; Paul, A.; Peixoto, P.; Nhili, R.; Marongiu, L.; Figeac, M.; Dassi, C.; Paul-Constant, C.; et al. Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model. *J. Med. Chem.* **2019**, *62*, 1306–1329. [[Google Scholar](#)] [[CrossRef](#)]
13. Patel, A.; Smith, H.J.; Sturzebecher, J. *Introduction to the Principles of Drug Design and Action*; Smith, H.J., Ed.; CRC Taylor & Francis: Boca Raton, FL, USA, 2006. [[Google Scholar](#)]
14. Tanious, F.A.; Hamelberg, D.; Bailly, C.; Czarny, A.; Boykin, D.W.; Wilson, W.D. DNA Sequence Dependent Monomer–Dimer Binding Modulation of Asymmetric Benzimidazole Derivatives. *J. Am. Chem. Soc.* **2004**, *126*, 143–153. [[Google Scholar](#)] [[CrossRef](#)]
15. Racané, L.; Tralić-Kulenović, V.; Kraljević Pavelić, S.; Ratkaj, I.; Peixoto, P.; Nhili, R.; Depauw, S.; Hildebrand, M.P.; David-Cordonnier, M.H.; Pavelić, K.; et al. Novel Diamidino-Substituted Derivatives of Phenyl Benzothiazolyl and Dibenzothiazolyl Furans and Thiophenes: Synthesis, Antiproliferative and DNA Binding Properties. *J. Med. Chem.* **2010**, *53*, 2418–2432. [[Google Scholar](#)] [[CrossRef](#)]
16. Racané, L.; Kraljević Pavelić, S.; Nhili, R.; Depauw, S.; Paul-Constant, C.; Ratkaj, I.; David-Cordonnier, M.H.; Pavelić, K.; Tralić-Kulenović, V.; Karminski-Zamola, G. New anticancer active and selective phenylene-bisbenzothiazoles: Synthesis, antiproliferative evaluation and DNA binding. *Eur. J. Med. Chem.* **2013**, *63*, 882–891. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]

17. Hranjec, M.; Kralj, M.; Piantanida, I.; Sedić, M.; Šuman, L.; Pavelić, K.; Karminski-Zamola, G. Novel Cyano- and Amidino-Substituted Derivatives of Styryl-2-Benzimidazoles and Benzimidazo[1,2-a]quinolines. Synthesis, Photochemical Synthesis, DNA Binding, and Antitumor Evaluation, Part 3. *J. Med. Chem.* **2007**, *50*, 5696–5711. [[Google Scholar](#)] [[CrossRef](#)]
18. Perin, N.; Nhili, R.; Ester, K.; Laine, W.; Karminski-Zamola, G.; Kralj, M.; David-Cordonnier, M.H.; Hranjec, M. Synthesis, antiproliferative activity and DNA binding properties of novel 5-Aminobenzimidazo [1, 2-a] quinoline-6-carbonitriles. *Eur. J. Med. Chem.* **2014**, *80*, 218–227. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
19. Loncar, B.; Perin, N.; Mioc, M.; Bocek, I.; Grgic, L.; Kralj, M.; Tomic, S.; Radic Stojkovic, M.; Hranjec, M. Novel amino substituted tetracyclic imidazo[4,5-b]pyridine derivatives: Design, synthesis, antiproliferative activity and DNA/RNA binding study. *Eur. J. Med. Chem.* **2021**, *217*, 113342. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
20. Racané, L.; Stojković, R.; Tralić-Kulenović, V.; Cerić, H.; Đaković, M.; Ester, K.; Mišir Krpan, A.; Radić Stojković, M. Interactions with polynucleotides and antitumor activity of amidino and imidazoliny substituted 2-phenylbenzothiazole mesylates. *Eur. J. Med. Chem.* **2014**, *86*, 406–419. [[Google Scholar](#)] [[CrossRef](#)]
21. Mandal S, Vishvakarma P. Nanoemulgel: A Smarter Topical Lipidic Emulsion-based Nanocarrier. *Indian J of Pharmaceutical Education and Research.* 2023;57(3s):s481-s498.
22. Mandal S, Jaiswal DV, Shiva K. A review on marketed Carica papaya leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. *International Journal of Pharmaceutical Research.* 2020 Jul;12(3).
23. Pal N, Mandal S, Shiva K, Kumar B. Pharmacognostical, Phytochemical and Pharmacological Evaluation of Mallotus philippensis. *Journal of Drug Delivery and Therapeutics.* 2022 Sep 20;12(5):175-81.
24. Singh A, Mandal S. Ajwain (*Trachyspermum ammi* Linn): A review on Tremendous Herbal Plant with Various Pharmacological Activity. *International Journal of Recent Advances in Multidisciplinary Topics.* 2021 Jun 9;2(6):36-8.
25. Mandal S, Jaiswal V, Sagar MK, Kumar S. Formulation and evaluation of carica papaya nanoemulsion for treatment of dengue and thrombocytopenia. *Plant Arch.* 2021;21:1345-54.
26. Mandal S, Shiva K, Kumar KP, Goel S, Patel RK, Sharma S, Chaudhary R, Bhati A, Pal N, Dixit AK. Ocular drug delivery system (ODDS): Exploration the challenges and approaches to improve ODDS. *Journal of Pharmaceutical and Biological Sciences.* 2021 Jul 1;9(2):88-94.
27. Shiva K, Mandal S, Kumar S. Formulation and evaluation of topical antifungal gel of fluconazole using aloe vera gel. *Int J Sci Res Develop.* 2021;1:187-93.
28. Ali S, Farooqui NA, Ahmad S, Salman M, Mandal S. *Catharanthus roseus* (sadabahar): a brief study on medicinal plant having different pharmacological activities. *Plant Archives.* 2021;21(2):556-9.
29. Mandal S, Vishvakarma P, Verma M, Alam MS, Agrawal A, Mishra A. *Solanum Nigrum* Linn: An Analysis Of The Medicinal Properties Of The Plant. *Journal of Pharmaceutical Negative Results.* 2023 Jan 1:1595-600.
30. Vishvakarma P, Mandal S, Pandey J, Bhatt AK, Banerjee VB, Gupta JK. An Analysis Of The Most Recent Trends In Flavoring Herbal Medicines In Today's Market. *Journal of Pharmaceutical Negative Results.* 2022 Dec 31:9189-98.
31. Mandal S, Vishvakarma P, Mandal S. Future Aspects And Applications Of Nanoemulgel Formulation For Topical Lipophilic Drug Delivery. *European Journal of Molecular & Clinical Medicine.*;10(01):2023.
32. Chawla A, Mandal S, Vishvakarma P, Nile NP, Lokhande VN, Kakad VK, Chawla A. Ultra-Performance Liquid Chromatography (Uplc).
33. Mandal S, Raju D, Namdeo P, Patel A, Bhatt AK, Gupta JK, Haneef M, Vishvakarma P, Sharma UK. Development, characterization, and evaluation of rosa alba l extract-loaded phytosomes.

34. Shaharyar M, Mazumder A. Benzimidazoles: A biologically active compounds. *Arabian Journal of Chemistry*. 2017 Feb 1;10:S157-73. <https://doi.org/10.1016/j.arabjc.2012.07.017>.
35. Satija G, Sharma B, Madan A, Iqubal A, Shaquiquzzaman M, Akhter M, Parvez S, Khan MA, Alam MM. Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets. *Journal of Heterocyclic Chemistry*. 2022 Jan;59(1):22
36. Praneetha V, Rani SU, Srinivas K. Synthesis and Invitro Anti-Inflammatory activity of some 1, 2-disubstituted benzimidazoles. *Asian Journal of Research in Chemistry*. 2016;9(10):462-8.
37. Cindrić, M.; Jambon, S.; Harej, A.; Depauw, S.; David-Cordonnier, M.H.; Kraljević Pavelić, S.; Karminski-Zamola, G.; Hranjec, M. Novel amidino substituted benzimidazole and benzothiazole benzo[b]thieno-2-carboxamides exert strong antiproliferative and DNA binding properties. *Eur. J. Med. Chem.* **2017**, *136*, 468–479. [[Google Scholar](#)] [[CrossRef](#)]
38. King, H.; Lourie, E.M.; Yorke, W. Studies in chemotherapy. XIX. Further report on new trypanocidal substances. *Ann. Trop. Med. Parasitol.* **1938**, *32*, 177–192. [[Google Scholar](#)] [[CrossRef](#)]
39. Lourie, E.M.; Yorke, W. Studies in chemotherapy. XVI. The trypanocidal action of synthalin. *Ann. Trop. Med. Parasitol.* **1939**, *33*, 289–304. [[Google Scholar](#)] [[CrossRef](#)]
40. Lombardy, R.L.; Tanious, F.A.; Ramachandran, K.; Tidwell, R.R.; Wilson, W.D. Synthesis and DNA Interactions of Benzimidazole Dications Which Have Activity against Opportunistic Infections. *J. Med. Chem.* **1996**, *39*, 1452–1462. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
41. Blagburn, B.L.; Sundermann, C.A.; Lindsay, D.S.; Hall, J.E.; Tidwell, R.R. Inhibition of *Cryptosporidium parvum* in neonatal Hsd:(ICR)BR Swiss mice by polyether ionophores and aromatic amidines. *Antimicrob. Agents Chemother.* **1991**, *35*, 1520–1523. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)] [[Green Version](#)]
42. Mazur, S.; Tanious, F.; Ding, D.; Kumar, A.; Boykin, D.W.; Neidle, S.; Wilson, W.D. A thermodynamic and structural analysis of DNA minor-groove complex formation. *J. Mol. Biol.* **2000**, *300*, 321–337. [[Google Scholar](#)] [[CrossRef](#)]
43. Das, B.P.; Boykin, D.W. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)thiophenes and -pyrroles. *J. Med. Chem.* **1977**, *20*, 1219–1221. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
44. Tidwell, R.R.; Bell, C.A. *Pentamidine and Related Compounds in Treatment of Pneumocystis Carinii Infection*. *Pneumocystis carinii*; Marcel Decker: New York, NY, USA, 1993; p. 561. [[Google Scholar](#)]
45. Hopkins, K.T.; Wilson, W.D.; Bender, B.C.; McCurdy, D.R.; Hall, J.E.; Tidwell, R.R.; Kumar, A.; Bajic, M.; Boykin, D.W. Extended aromatic furan amidino derivatives as anti-Pneumocystis carinii agents. *J. Med. Chem.* **1998**, *41*, 3872–3878. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
46. Boykin, D.W.; Kumar, A.; Xiao, G.; Wilson, W.D.; Bender, B.C.; McCurdy, D.R.; Hall, J.E.; Tidwell, R.R. 2,5-Bis[4-(N-alkylamidino)phenyl]furans as Anti-Pneumocystis carinii Agents. *J. Med. Chem.* **1998**, *41*, 124–129. [[Google Scholar](#)] [[CrossRef](#)]
47. Ismail, M.A.; Brun, R.; Easterbrook, J.D.; Tanious, F.A.; Wilson, W.D.; Boykin, D.W. Synthesis and Antiprotozoal Activity of Aza-Analogues of Furamidine. *J. Med. Chem.* **2003**, *46*, 4761–4769. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
48. Brajša, K.; Trzun, M.; Zlatar, I.; Jelić, D. Three-dimensional cell cultures as a new tool in drug discovery. *Period. Biliogorum* **2016**, *118*, 59–65. [[Google Scholar](#)] [[CrossRef](#)]
49. Zlatar, I.; Jelić, D.; Kelava, V.; Cindrić, M.; Jarak, I.; Koštrun, S.; Karminski-Zamola, G.; Gabelica Marković, V.; Hranjec, M.; Brajša, K. Comparison of Antitumor Activity of Some Benzothiophene and Thienothiophene Carboxanilides and Quinolones in 2D and 3D Cell Culture System. *Croat. Chem. Act.* **2017**, *90*, 413–424. [[Google Scholar](#)] [[CrossRef](#)]
50. Perin, N.; Bobanović, K.; Zlatar, I.; Jelić, D.; Kelava, V.; Koštrun, S.; Gabelica Marković, V.; Brajša, K.; Hranjec, M. Antiproliferative activity of amino substituted benzo[b]thieno[2,3-b]pyrido[1,2-a]benzimidazoles explored by 2D and 3D cell culture system. *Eur. J. Med. Chem.* **2017**, *125*, 722–735. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]

51. Alotaibi, S.H.; Momen, A.A. Anticancer Drugs' Deoxyribonucleic Acid (DNA) Interactions. In *Biophysical Chemistry-Advance Applications*; Khalid, M., Ed.; IntechOpen: London, UK, 2019; Available online: <https://www.intechopen.com/books/biophysical-chemistry-advance-applications/anticancer-drugs-deoxyribonucleic-acid-dna-interactions> (accessed on 14 July 2021). [CrossRef][Green Version]
52. Racané, L.; Ptiček, L.; Fajdetić, G.; Tralić-Kulenović, V.; Klobučar, M.; Kraljević Pavelić, S.; Perić, M.; Čipčić Paljetak, H.; Verbanac, D.; Starčević, K. Green synthesis and biological evaluation of 6-substituted-2-(2-hydroxy/methoxy phenyl)benzothiazole derivatives as potential antioxidant, antibacterial and antitumor agents. *Bioorg. Chem.* **2020**, *95*, 103537. [Google Scholar] [CrossRef] [PubMed]
53. Racané, L.; Tralić-Kulenović, V.; Mihalić, Z.; Pavlović, G.; Karminski-Zamola, G. Synthesis of new amidino-substituted 2-aminothiophenoles: Mild basic ring opening of benzothiazole. *Tetrahedron* **2008**, *64*, 11594–11602. [Google Scholar] [CrossRef]
54. Hranjec, M.; Pavlović, G.; Marjanović, M.; Karminski-Zamola, G. Benzimidazole derivatives related to 2,3-acrylonitriles, benzimidazo[1,2-a]quinolines and fluorenes. *Eur. J. Med. Chem.* **2010**, *45*, 2405–2417. [Google Scholar] [CrossRef]
55. Estman, A. Improving anticancer drug development begins with cell culture: Misinformation perpetrated by the misuse of cytotoxicity assays. *Oncotarget* **2017**, *8*, 8854–8866. [Google Scholar] [CrossRef][Green Version]
56. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63. [Google Scholar] [CrossRef]
57. Parish, J. *Principles of Nucleic Acid Structure*; Saenger, W., Ed.; Springer: New York, NY, USA, 1984; p. 556, DM 79; ISBN 3-540-90761-0. [Google Scholar]
58. Scatchard, G. The attractions of proteins for small molecules and ions. *Ann. N. Y. Acad. Sci.* **1949**, *51*, 660–672. [Google Scholar] [CrossRef]
59. Mergny, J.L.; Lacroix, L. Analysis of thermal melting curves. *Oligonucleotides* **2003**, *13*, 515–537. [Google Scholar] [CrossRef] [PubMed]
60. Demeunynck, M.; Bailly, C.; Wilson, W.D. *DNA and RNA Binders: From Small Molecules to Drugs*; Wiley-VCH: Weinheim, Germany, 2002; Volume 1, Chapter 5. [Google Scholar]
61. Rodger, A.; Nordén, B. *Circular Dichroism and Linear Dichroism*; Oxford University Press: New York, NY, USA, 1997. [Google Scholar]
62. Eriksson, M.; Nordén, B. Linear and circular dichroism of drug-nucleic acid complexes. *Methods Enzymol.* **2001**, *340*, 68–98. [Google Scholar]
63. Šmidlehner, T.; Piantanida, I.; Pescitelli, G. Polarization spectroscopy methods in the determination of interactions of small molecules with nucleic acids—tutorial. *Beilstein J. Org. Chem.* **2017**, *14*, 84–105. [Google Scholar] [CrossRef] [PubMed]
64. Jezuita, A.; Ejsmont, K.; Szatyłowicz, H. Substituent effects of nitro group in cyclic compounds. *Struct. Chem.* **2021**, *32*, 179–203. [Google Scholar] [CrossRef]
65. Neidle, S. *Oxford Handbook of Nucleic Acid Structure*; Oxford University Press: Oxford, UK, 1999. [Google Scholar]
66. Ganushchak, N.I.; Lesyuk, A.I.; Fedorovich, I.S.; Obushak, N.D.; Andrushko, V.N. 5-Aryl-2-furaldehydes in the Synthesis of 2-Substituted 1,3-Benzazoles. *Russ. J. Org. Chem.* **2003**, *39*, 1295–1300. [Google Scholar] [CrossRef]
67. Chaires, J.B.; Dattagupta, N.; Crothers, D.M. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: Equilibrium binding studies on the interaction of daunomycin with deoxyribonucleic acid. *Biochemistry* **1982**, *21*, 3933–3940. [Google Scholar] [CrossRef]
68. Chalikian, T.V.; Volker, J.; Plum, G.E.; Breslauer, K.J.A. A more unified picture for the thermodynamics of nucleic acid duplex melting: A characterization by calorimetric and volumetric techniques. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 7853–7858. [Google Scholar] [CrossRef] [PubMed][Green Version]

69. Trinquet, E.; Mathis, G. Fluorescence technologies for the investigation of chemical libraries. *Mol. Biosyst.* **2006**, *2*, 380–387. [[Google Scholar](#)] [[CrossRef](#)]
70. Kurutos, A.; Crnolatac, I.; Orehovec, I.; Gadjev, N.; Piantanida, I.; Deligeorgiev, T. Novel synthetic approach to asymmetric monocationic trimethine cyanine dyes derived from N-ethyl quinolinium moiety. Combined fluorescent and ICD probes for AT-DNA labelling. *J. Lumin.* **2016**, *174*, 70–76. [[Google Scholar](#)] [[CrossRef](#)]
71. Tumir, L.M.; Crnolatac, I.; Deligeorgiev, T.; Vasilev, A.; Kaloyanova, S.; Grabar Branilović, M.; Tomić, S.; Piantanida, I. Kinetic Differentiation between Homo- and Alternating AT DNA by Sterically Restricted Phosphonium Dyes. *Chem. Eur. J.* **2012**, *18*, 3859–3864. [[Google Scholar](#)] [[CrossRef](#)]
72. Stefl, R.; Wu, H.; Ravindranathan, S.; Sklenář, V.; Feigon, J. DNA A-tract bending in three dimensions: Solving the dA4T4 vs. dT4A4 conundrum. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 1177–1182. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)][[Green Version](#)]